This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third View: Discussing the potential of Amgen's LUMAKRAS (sotorasib) in 2nd-line NSCLC with KRAS G12C mutation.

Ticker(s): AMGN

Who's the expert?

Institution: Ironwood Cancer and Research Center

  • Treats 100 patients with NSCLC and has prescribed Lumrakras several times

Dr. Jason Salganick is a Medical Oncologist in Phoenix, AZ. He joined Ironwood Cancer & Research Centers in May 2013. He also serves as an Assistant Clinical Professor with Creighton University. Dr. Salganick was born on the Mexican Border in Chula Vista, California into a bilingual home. His mother is Puerto Rican and his father is of Russian Jewish origin and he is fluent in both English and Spanish. He graduated Princeton University with a B.A. in Medieval History, but not before taking a one-year leave of absence for Medieval Studies at Oxford University. After completing medical school at the University of Chicago, Pritzker School of Medicine he went on to complete a combined Internal Medicine/Pediatrics Internship and Residency at Tulane University Medical Center in New Orleans, LA. There, he was a 2-Term Chairman for Resident Physician Section with the Louisiana State Medical Society and led the Louisiana delegation to the 1997 American Medical Association National Meeting in Honolulu, Hawaii. He designed and completed a combined Fellowship in Medical Oncology and Pediatric Hematology/Oncology at MD Anderson Cancer Center in Houston, TX. He is credited with several scientific papers, the most recent of which was published in March, 2013 in Cancer Medicine. He is Chairman of the Honor Health North Mountain Tumor Board. In San Francisco he met and married his wife, Robbyn Salganick, a corporate attorney who presently has only their three children as her clients whom she represents with vigor. Dr. Salganick is a member of the American Society of Clinical Oncology, the American Medical Association and the Arizona Latino Medical Association, and has been a part of the Phoenix medical oncology community since 2008. He enjoys Salsa Dancing, Scuba Diving and General Aviation.

Interview Goal
Discussing the potential of Amgen's LUMAKRAS (sotorasib) in 2nd-line NSCLC with KRAS G12C mutation.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.